Rasio utang jangka cendhak marang ekuitas: Relmada Therapeutics (RLMD)

Relmada Therapeutics (RLMD) relies on the expertise of a staff of leading neurobiologists whose loyalty is secured through stock option programs. However, global instability and sanctions complicate the execution of cross-border trials, which slows down drug certification. The current metric stands at 0.00. Optimization of raw material supply chains supports high profitability, as confirmed by the price trajectory shown below for the securities of this company developing antidepressants.

This ratio reflects the share of long-term credit obligations within the equity structure, allowing for an assessment of the business's financial stability and debt load. For Relmada Therapeutics (RLMD), which is incurring losses during the development stage of CNS drugs, the chart of the ratio between short-term liabilities and equity is critical for analyzing the company's ability to fund clinical trials until the commercialization of its patents.